Amylyx Pharmaceuticals, Inc. AMLX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $229.14M+1.1% | $226.65M+0.7% | $225.18M+288% | $58.09M-2.8% | $59.76M-22.8% | ||
| $50.63M-43.9% | $90.33M-24.0% | $118.81M-3.2% | $122.74M-14.9% | $144.3M+45.6% | ||
| $27.17M-19.4% | $33.69M-14.7% | $39.48M+0.3% | $39.36M-14.8% | $46.22M-10.0% | ||
| $285.02M-11.9% | $323.67M-8.4% | $353.38M+89.1% | $186.89M-13.5% | $216.14M+14.1% | ||
| $212K-31.6% | $310K-22.3% | $399K-10.3% | $445K-45.5% | $816K-15.1% | ||
| $4.88M-5.8% | $5.18M-5.4% | $5.48M-5.8% | $5.81M+363% | $1.26M-29.1% | ||
| —— | —— | —— | —— | $11K-54.2% | ||
| $293.6M-11.7% | $332.65M-8.3% | $362.74M+86.4% | $194.6M-11.4% | $219.68M+13.4% | ||
| $15.68M-7.6% | $16.96M+3.5% | $16.38M+30.7% | $12.53M-11.7% | $14.19M-54.0% | ||
| $11.28M-37.0% | $17.91M-8.0% | $19.47M+11.5% | $17.47M+44.7% | $12.07M-49.6% | ||
| $1.16M-8.3% | $1.26M+28.3% | $981K+47.5% | $665K-37.0% | $1.06M-30.5% | ||
| $15.97M-29.6% | $22.69M-12.0% | $25.79M+20.4% | $21.42M+19.5% | $17.93M-36.9% | ||
| $4.48M-4.7% | $4.7M-5.2% | $4.95M-6.5% | $5.3M+1,520% | $327K-29.4% | ||
| $20.44M-25.4% | $27.39M-10.9% | $30.75M+15.1% | $26.72M+46.3% | $18.26M-36.8% | ||
| $11K0.0% | $11K0.0% | $11K+22.2% | $9K0.0% | $9K+28.6% | ||
| $1.07B+0.9% | $1.06B+0.6% | $1.05B+23.3% | $851.36M+0.9% | $844.01M+9.4% | ||
| -$792.71M-5.5% | -$751.43M-4.6% | -$718.43M-5.0% | -$684.04M-6.4% | -$642.6M-5.9% | ||
| $240K-40.6% | $404K-50.4% | $815K+47.9% | $551K— | $0+100% | ||
| $273.16M-10.5% | $305.26M-8.1% | $332M+97.8% | $167.88M-16.7% | $201.42M+22.2% | ||
| $293.6M-11.7% | $332.65M-8.3% | $362.74M+86.4% | $194.6M-11.4% | $219.68M+13.4% | ||
| $50.63M-43.9% | $90.33M-24.0% | $118.81M-3.2% | $122.74M— | —— | ||
| —— | —— | —— | —— | $11K-54.2% | ||
| $4.88M-5.8% | $5.18M-5.4% | $5.48M-5.8% | $5.81M+363% | $1.26M-29.1% | ||
| —— | —— | —— | —— | —— | ||
| $4.88M-5.8% | $5.18M-5.4% | $5.48M-5.8% | $5.81M+363% | $1.26M-29.1% | ||
| —— | —— | —— | —— | $11K-54.2% | ||
| $4.88M-5.8% | $5.18M-5.4% | $5.48M-5.8% | $5.81M+363% | $1.26M-29.1% | ||
| —— | —— | —— | —— | $11K-54.2% | ||
| $11.28M-37.0% | $17.91M-8.0% | $19.47M+11.5% | $17.47M+44.7% | $12.07M-49.6% | ||
| $11.28M-37.0% | $17.91M-8.0% | $19.47M+11.5% | $17.47M+44.7% | $12.07M-49.6% | ||
| $5.63M-5.5% | $5.96M+0.4% | $5.94M-0.5% | $5.96M+331% | $1.38M-30.2% | ||
| $1.07B+0.9% | $1.06B+0.6% | $1.05B+23.3% | $851.36M+0.9% | $844.01M+9.4% | ||
| $11K0.0% | $11K0.0% | $11K+22.2% | $9K0.0% | $9K+28.6% | ||
| $986K+0.1% | $985K+0.2% | $983K-32.3% | $1.45M+0.1% | $1.45M+0.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Amylyx Pharmaceuticals, Inc.'s total assets?
- Amylyx Pharmaceuticals, Inc. (AMLX) holds $293.6M in total assets, up 33.7% year over year.
- How much debt does Amylyx Pharmaceuticals, Inc. have?
- Amylyx Pharmaceuticals, Inc. carries $5.6M in total debt against $273.2M of shareholders' equity, a debt-to-equity ratio of 0.02.
- How much cash does Amylyx Pharmaceuticals, Inc. have?
- Amylyx Pharmaceuticals, Inc. holds $229.1M in cash and equivalents.
- Can Amylyx Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 17.85 — current assets exceed current liabilities.
- Where does Amylyx Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.